Receive our newsletter – data, insights and analysis delivered to you
  1. News
June 9, 2016

GenMark Diagnostics secures CE mark for ePlex Instrument System and ePlex RP panel

US-based medical device company GenMark Diagnostics has received the CE mark approval for its ePlex Instrument System and ePlex Respiratory Pathogen (RP) Panel.

US-based medical device company GenMark Diagnostics has received the CE mark approval for its ePlex Instrument System and ePlex Respiratory Pathogen (RP) Panel.

A sample-to-answer multiplex molecular diagnostics system, ePlex integrates sample preparation steps including extraction and amplification, together with the company’s patented eSensor detection technology.

The integration facilitates detection of multiple molecular targets on a single test cartridge.

"Interest in ePlex has remained very strong as evidenced by the more than 15 European customer agreements we have already secured."

The ePlex RP Panel is the first of many assays and is expected to be made available on the ePlex System. It detects 20 viral and three bacterial targets in nasopharyngeal specimens in less than two minutes of operators’ hands-on time.

GenMark president and CEO Hany Massarany said: "Achieving CE Mark for ePlex has been an important goal for our Company.

"We are delighted to have accomplished this key milestone and are now focused on installing ePlex Systems in European early adopter customer sites.

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 

"Interest in ePlex has remained very strong as evidenced by the more than 15 European customer agreements we have already secured."

GenMark is also installing the ePlex Systems into US clinical trials in order to complete the essential clinical studies to secure clearance of the ePlex System and RP Panel from the US Food and Drug Administration (FDA).

The studies are expected to be completed during the third quarter of this year, with FDA submission is expected to be carried out towards the end of the third quarter or beginning of the fourth quarter of this year.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU